Home / Combinations / Semaglutide + Tesamorelin
Semaglutide + Tesamorelin
Targeted Fat Loss
A dual-mechanism fat loss stack combining semaglutide's appetite suppression and GLP-1-mediated metabolic benefits with tesamorelin's targeted visceral fat reduction through GHRH agonism. Semaglutide promotes a sustained caloric deficit and improves insulin sensitivity, while tesamorelin specifically mobilises deep abdominal visceral adipose tissue by stimulating pulsatile GH release. The two agents operate through entirely non-overlapping pathways and address different fat compartments.
Stack components
What each compound is researched for on its own. Nothing here describes an interaction between them.
Semaglutide
Reduces appetite and caloric intake via GLP-1 receptor agonism, improves insulin sensitivity, and drives broad body composition improvements — serving as the primary overall fat loss driver of the stack.
Tesamorelin
Specifically targets visceral adipose tissue via GHRH-stimulated GH pulses that preferentially mobilise deep abdominal fat, addressing a metabolically harmful fat depot that GLP-1 agonism alone may not fully resolve.
Semaglutide is an FDA-approved prescription GLP-1 agonist carrying a boxed warning for thyroid C-cell tumour risk (observed in rodents; human risk not established). It requires a licensed prescriber and is contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy; its use for general fat loss is off-label and outside its approved indication. This is a prescription-only combination not appropriate for unsupervised use.
Author-written. Not derived from any compound field, and not covered by the profile-integrity audit that gates the peptide pages.
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.